YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma

In brief

This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.

Key facts

Study ID

NCT05448820

Run by

Tracon Pharmaceuticals Inc.

People needed

15

Starts

2022-11-14

Expected to finish

2025-09-01

Last updated by the study team

2023-09-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed advanced or metastatic sarcoma patients without UPS or MFS who are refractory to or intolerant to standard treatments for their disease.
• Histologically confirmed advanced or metastatic sarcoma patients without UPS or MFS who have not received any immune checkpoint inhibitors or doxorubicin, and with histology for which doxorubicin is considered a reasonable treatment option (for Cohort 1B, 2B and Expanded Cohort 1B and/or 2B)
• Measurable disease by RECIST 1.1
• Age ≥ 18 years
• Adequate organ function
• Left ventricular ejection fraction (LVEF) as measured by echo or multigated acquisition scan of > 50% (for patients to receive doxorubicin)
• Willingness and ability to consent for self to participate in study
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
• Men who are sterile or agree to use a condom with spermicide .
• Women of non-child bearing potential due to surgical sterilization or medically-documented ovarian failure confirmed by medical history, or women of child bearing potential who test negative for pregnancy at time of enrollment and agree to use at least 2 acceptable methods of birth control

You may not qualify if…

• Gastrointestinal stromal tumor (GIST) or desmoid tumors
• Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to enrollment
• Known allergy to any component of any study drug that the patient would receive if enrolled into this study
• Prior T-cell or NK-cell therapy
• Prior pericardial or mediastinal radiation (for patients to receive doxorubicin)
• Acute coronary syndromes within 6 months of enrollment
• Women who are pregnant or breast feeding
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study

Where it is running

• Sarcoma Oncology Center — Santa Monica, California, United States
• Northwestern University — Chicago, Illinois, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Duke University — Durham, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.